Department of Gastroenterology and Hepatology, Amsterdam UMC, location University of Amsterdam, Amsterdam, The Netherlands.
Amsterdam Gastroenterology Endocrinology Metabolism, Research Institute, Amsterdam, The Netherlands.
Endoscopy. 2024 Jan;56(1):47-52. doi: 10.1055/a-2134-3537. Epub 2023 Jul 20.
This study aimed to assess the safety and feasibility of endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) using a lumen-apposing metal stent (LAMS) as a primary drainage strategy in patients with distal malignant biliary obstruction (MBO).
A prospective, single-center, pilot study was conducted in patients with pathology-confirmed MBO without gastric outlet obstruction. The primary outcome was technical success. Secondary outcomes included clinical success, adverse events (AEs), and reinterventions. The study was registered in the Netherlands Trial Registry (registry number NL9757).
22 patients were enrolled (median age 69.5 years [interquartile range 64-75.3]). Technical success was achieved in 20/22 patients (91 %). AEs occurred in one patient, namely perforation following inadequate stent deployment (5 %), which was treated in the same procedure. Clinical success was achieved in 19/22 patients (86 %). Stent dysfunction was observed in 11/20 patients (55 %) after technically successful EUS-CDS: two patients were treated conservatively and nine patients underwent reintervention(s). One patient died within ≤ 30 days due to fulminant disease progression.
The results confirmed the safety and feasibility of EUS-CDS using LAMS as a primary drainage strategy. The high incidence of stent dysfunction should be improved before EUS-CDS with LAMS can be seen as a valid alternative to endoscopic retrograde cholangiopancreatography.
本研究旨在评估经内镜超声引导下胆肠吻合术(EUS-CDS)使用 lumen-apposing 金属支架(LAMS)作为远端恶性胆道梗阻(MBO)患者主要引流策略的安全性和可行性。
对病理证实的无胃出口梗阻的 MBO 患者进行前瞻性、单中心、试点研究。主要结局是技术成功率。次要结局包括临床成功率、不良事件(AEs)和再干预。该研究在荷兰试验注册处(注册号 NL9757)注册。
共纳入 22 例患者(中位年龄 69.5 岁[四分位距 64-75.3])。20/22 例(91%)患者达到技术成功。1 例患者发生 AEs,即支架放置不足导致穿孔(5%),在同一手术中进行了治疗。19/22 例(86%)患者达到临床成功。技术上成功的 EUS-CDS 后,20 例中有 11 例(55%)出现支架功能障碍:2 例患者接受保守治疗,9 例患者接受再干预。1 例患者在≤30 天内死于疾病迅速恶化。
结果证实了使用 LAMS 作为主要引流策略的 EUS-CDS 的安全性和可行性。在 LAMS 联合 EUS-CDS 可以被视为内镜逆行胰胆管造影术的有效替代方法之前,应改善支架功能障碍的高发率。